PXS-5505 HCl
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H207207

CAS#: 2409964-23-2 (HCl)

Description: PXS-5505 is a Pan-Lysyl Oxidase Inhibitor that has been found to ameliorate multiple-organ fibrosis by inhibiting collagen crosslinks in rodent models in systemic sclerosis. PXS-5505 inhibited lysyl oxidase activity in the skin and LOXL2 activity in the lung. PXS-5505 exhibited anti-fibrotic effects in the SSc skin mouse model, reducing dermal thickness and α-smooth muscle actin. Similarly, in the bleomycin-induced mouse lung model, PXS-5505 reduced pulmonary fibrosis toward normal levels, mediated by its ability to normalise collagen/elastin crosslink formation. PXS-5505 also reduced fibrotic extent in models of the ischaemia-reperfusion heart, the unilateral ureteral obstruction kidney, and the CCl4-induced fibrotic liver.


Chemical Structure

img
PXS-5505 HCl
CAS# 2409964-23-2 (HCl)

Theoretical Analysis

Hodoodo Cat#: H207207
Name: PXS-5505 HCl
CAS#: 2409964-23-2 (HCl)
Chemical Formula: C13H15Cl2FN2O2S
Exact Mass: 0.00
Molecular Weight: 353.230
Elemental Analysis: C, 44.20; H, 4.28; Cl, 20.07; F, 5.38; N, 7.93; O, 9.06; S, 9.08

Price and Availability

Size Price Availability Quantity
5mg USD 150 2 Weeks
10mg USD 250 Ready to ship
25mg USD 450 Ready to ship
50mg USD 750 Ready to ship
100mg USD 1250 Ready to ship
200mg USD 1950 Ready to ship
500mg USD 2950 Ready to ship
1g USD 4650 Ready to ship
2g USD 7250 Ready to ship
Bulk inquiry

Related CAS #: 2409963-83-1 (free base)   2409964-23-2 (HCl)    

Synonym: PXS-5505 HCl; PXS-5505 2HCl; PXS-5505 dihydrochloride; PXS-5505; PXS 5505; PXS5505;

IUPAC/Chemical Name: (Z)-3-Fluoro-4-quinolin-8-ylsulfonylbut-2-en-1-amine dihyrochloride

InChi Key: YYYHSAUHJBNINZ-LEOXJOGCSA-N

InChi Code: InChI=1S/C13H13FN2O2S.2ClH/c14-11(6-7-15)9-19(17,18)12-5-1-3-10-4-2-8-16-13(10)12;;/h1-6,8H,7,9,15H2;2*1H/b11-6-;;

SMILES Code: NC/C=C(F)/CS(=O)(C1=C2N=CC=CC2=CC=C1)=O.[H]Cl.[H]Cl

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 353.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Xu Q, Streuer A, Jann JC, Altrock E, Schmitt N, Flach J, Sens-Albert C, Rapp F, Wolf J, Nowak V, Weimer N, Obländer J, Palme I, Kuzina M, Jawhar A, Darwich A, Weis CA, Marx A, Wuchter P, Costina V, Jäger E, Sperk E, Neumaier M, Fabarius A, Metzgeroth G, Nolte F, Steiner L, Levkin PA, Jawhar M, Hofmann WK, Riabov V, Nowak D. Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies. Nat Commun. 2023 Mar 17;14(1):1497. doi: 10.1038/s41467-023-37175-8. PMID: 36932114; PMCID: PMC10023686.


2: Yao Y, Findlay A, Stolp J, Rayner B, Ask K, Jarolimek W. Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis. Int J Mol Sci. 2022 May 16;23(10):5533. doi: 10.3390/ijms23105533. PMID: 35628342; PMCID: PMC9146019.


3: Perryman L, Gray SG. Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases. Cancers (Basel). 2022 Feb 15;14(4):981. doi: 10.3390/cancers14040981. PMID: 35205728; PMCID: PMC8870010.


4: Nguyen LT, Saad S, Shi Y, Wang R, Chou ASY, Gill A, Yao Y, Jarolimek W, Pollock CA. Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse. Sci Rep. 2021 Jun 14;11(1):12437. doi: 10.1038/s41598-021-91772-5. PMID: 34127702; PMCID: PMC8203624.